VCE-004.8

Names

[ Name ]:
VCE-004.8

[Synonym ]:
VCE-004.8

Biological Activity

[Description]:

VCE-004.8, a semi-synthetic multitarget cannabinoquinoid, is a specific PPARγ and CB2 receptor dual agonist with potent anti-inflammatory activity[1]. VCE-004.8 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity[2].

[Related Catalog]:

Signaling Pathways >> Cell Cycle/DNA Damage >> PPAR

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Metabolic Enzyme/Protease >> HIF/HIF Prolyl-Hydroxylase

Research Areas >> Metabolic Disease

Signaling Pathways >> GPCR/G Protein >> Cannabinoid Receptor

[Target]

PPARγ

CB2

[In Vivo]

VCE-004.8 ( injection; 20 mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. VCE-004.8 can also significantly ameliorate glucose tolerance, reduce leptin levels (a marker of adiposity) and increase adiponectin and incretins (GLP-1 and GIP) levels[1].

[References]

[1]. Navarrete C, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflammation. 2018 Mar 1;15(1):64.

[2]. Palomares B, et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Sci Rep. 2018 Oct 31;8(1):16092.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₈H₃₅NO₃

[ Molecular Weight ]:
433.58

VCE-004.8

Names

Biological Activity

Chemical & Physical Properties

Related Compounds